Coluracetam (BCI-540; formerly MKC-231) is a nootropic belonging to the racetam family of drugs. It was originally developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug had failed to reach the endpoints in its clinical trials, it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from phase IIa clinical trials have suggested that it would be a possible medication for a comorbid major depressive disorder (MDD) with generalized anxiety disorder (GAD).
Koluraċetam molecular structure diagram from the DrugsPRO substance library.
Also known as: Bci-540, Mkc-231
Classification
Chemical: Racetam
Psychoactive: Nootropic
Psychoactive: Stimulant
Tag: Research-Chemical
Effects
Stimulation
Increased Heart Rate
Insomnia
Spontaneous Tactile Sensations
Physical Energy
Difficulty Falling Asleep
Memory Enhancement
Motivation Enhancement
Thought Connectivity
Anxiety Suppression
Dream Potentiation
Focus Enhancement
Color Enhancement
Visual Acuity Enhancement
Auditory Acuity Enhancement
Acuity Enhancement
Auditory Enhancement
Tactile Enhancement
Routes of Administration
Oral
Dosage
Threshold: 3 mg
Light: 5-10 mg
Common: 10-20 mg
Strong: 10-20 mg
Heavy: 50 mg+
Duration
Onset: 0.25-0.5 h
Peak: 0.5-2 h
Offset: 3-5 h
After Effects: 1-6 h
Total Duration: 3-6 h
Sublingual
Dosage
Threshold: 2 mg
Light: 5-8 mg
Common: 10-15 mg
Strong: 20-30 mg
Heavy: 30 mg+
Duration
Onset: 0.02-0.08 h
Peak: 0.5-1.5 h
Offset: 3-5 h
After Effects: 1-6 h
Total Duration: 3-5 h
Insufflated
Dosage
Common: 5-10 mg
Light: 2-5 mg
Strong: 10-20 mg
Threshold: 1 mg
Heavy: 20 mg
Duration
Onset: 0-0.1 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Coluracetam - DrugsPRO gwida tal-sustanza
Coluracetam: Coluracetam (BCI-540; formerly MKC-231) is a nootropic belonging to the racetam family of drugs. It was originally developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug had failed to reach the endpoints in its clinical trials, it was in
